Prestige Consumer Healthcare Inc banner

Prestige Consumer Healthcare Inc
NYSE:PBH

Watchlist Manager
Prestige Consumer Healthcare Inc Logo
Prestige Consumer Healthcare Inc
NYSE:PBH
Watchlist
Price: 55.09 USD -2.18% Market Closed
Market Cap: $2.6B

P/S

2.4
Current
20%
Cheaper
vs 3-y average of 3

Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.

P/S
2.4
=
Market Cap
$3.3B
/
Revenue
$1.1B

Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.

P/S
2.4
=
Market Cap
$3.3B
/
Revenue
$1.1B

Valuation Scenarios

Prestige Consumer Healthcare Inc is trading below its 3-year average

If P/S returns to its 3-Year Average (3), the stock would be worth $68.71 (25% upside from current price).

Statistics
Positive Scenarios
4/4
Maximum Downside
No Downside Scenarios
Maximum Upside
+25%
Average Upside
14%
Scenario P/S Value Implied Price Upside/Downside
Current Multiple 2.4 $55.09
0%
3-Year Average 3 $68.71
+25%
5-Year Average 2.8 $63.93
+16%
Industry Average 2.7 $61.49
+12%
Country Average 2.4 $56.42
+2%

Forward P/S
Today’s price vs future revenue

Today's Market Cap Revenue Forward P/S
$3.3B
/
Jan 2026
$1.1B
=
2.4
Current
$3.3B
/
Mar 2026
$1.1B
=
3
Forward
$3.3B
/
Mar 2027
$1.2B
=
2.8
Forward
$3.3B
/
Mar 2028
$1.2B
=
2.7
Forward
$3.3B
/
Mar 2029
$1.3B
=
2.6
Forward
$3.3B
/
Mar 2030
$1.3B
=
2.6
Forward
$3.3B
/
Mar 2031
$1.4B
=
2.4
Forward

Forward P/S shows whether today’s P/S still looks high or low once future revenue are taken into account.

Peer Comparison

All Multiples
P/S
P/E
All Countries
Close
Market Cap P/S P/E
US
Prestige Consumer Healthcare Inc
NYSE:PBH
2.6B USD 2.4 14.1
US
Eli Lilly and Co
NYSE:LLY
908.9B USD 12.6 36
US
Johnson & Johnson
NYSE:JNJ
547.1B USD 5.7 26
CH
Roche Holding AG
SIX:ROG
248.4B CHF 4.2 20.1
UK
AstraZeneca PLC
LSE:AZN
209.6B GBP 4.7 27.4
CH
Novartis AG
SIX:NOVN
221.1B CHF 5 20.7
US
Merck & Co Inc
NYSE:MRK
277.6B USD 4.2 31.1
IE
Endo International PLC
LSE:0Y5F
244.4B USD 105.4 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.2T DKK 4 12.1
US
Pfizer Inc
NYSE:PFE
149.7B USD 2.4 19.3
US
Bristol-Myers Squibb Co
NYSE:BMY
118.9B USD 407.7 4 516.9
P/E Multiple
Earnings Growth PEG
US
Prestige Consumer Healthcare Inc
NYSE:PBH
Average P/E: 472.4
14.1
4%
3.5
US
Eli Lilly and Co
NYSE:LLY
36
32%
1.1
US
Johnson & Johnson
NYSE:JNJ
26
8%
3.3
CH
Roche Holding AG
SIX:ROG
20.1
14%
1.4
UK
AstraZeneca PLC
LSE:AZN
27.4
25%
1.1
CH
Novartis AG
SIX:NOVN
20.7
14%
1.5
US
Merck & Co Inc
NYSE:MRK
31.1
14%
2.2
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -83.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
12.1
0%
N/A
US
Pfizer Inc
NYSE:PFE
19.3
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
4 516.9
648%
7

Market Distribution

In line with most companies in the United States of America
Percentile
49th
Based on 11 520 companies
49th percentile
2.4
Low
0 — 1.2
Typical Range
1.2 — 4.1
High
4.1 —
Distribution Statistics
the United States of America
Min 0
30th Percentile 1.2
Median 2.4
70th Percentile 4.1
Max 4 613 274.2

Prestige Consumer Healthcare Inc
Glance View

Prestige Consumer Healthcare Inc. has carved out its niche in the competitive realm of over-the-counter healthcare products with a distinct flair. Born out of a series of insightful acquisitions and strategic brand cultivations, the company has crafted a portfolio that caters to a broad spectrum of consumer health needs. It offers an expansive range of products, from well-known pain relievers and eye care items to gastrointestinal treatments and women’s health solutions. The cornerstone of Prestige's success lies in its acute understanding of consumer demand and its agile response to market trends. By developing and acquiring brands that are established household names—such as Clear Eyes, Chloraseptic, and Dramamine—the firm has effectively secured a reliable revenue stream. Each brand, while under the corporate umbrella of Prestige, thrives on its ability to resonate with consumers who seek trustworthy, easily accessible remedies. Central to Prestige’s business model is its adeptness at maintaining and enhancing brand equity. Through a blend of focused marketing strategies and disciplined cost management, the company ensures consistent visibility and availability of its products across key retail channels, including mass merchandisers, drug retailers, and e-commerce. Prestige's skillful navigation of the marketplace allows it to capitalize on scale economies and maintain healthy margins. Each product in its portfolio is not only a testament to its commitment to quality and efficacy but also to its strategic foresight in addressing the ever-evolving healthcare challenges faced by consumers. In essence, Prestige Consumer Healthcare Inc. thrives by blending astute brand management with a keen focus on consumer health trends, ensuring its position as a formidable player in the healthcare industry.

PBH Intrinsic Value
71.6 USD
Undervaluation 23%
Intrinsic Value
Price $55.09
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett